OTLK SEC Form 4 filings
Outlook Therapeutics, Inc. Latest Insider Trading Activity
The most recent employee insider trading activity for Outlook Therapeutics, Inc. was on June 2, 2026, when Haddadin Yezan Munther (Director) reported a purchase of 29,000 shares at $0.83 per share. For the past 1,746 days, OTLK has had 11 total insider transactions represented in the displayed records. This page shows up to the 10 most recent SEC Form 4 filing records on a 6-hour delay. Sign up for real-time updates and access to 20 years of historic insider trading data.
Insider Trading For OTLK Charted on Daily Candles. Scroll left or zoom out to load earlier candles (up to 2 years).
▲ Insider buy
▼ Insider sale
Loading daily price history…
Charting by TradingView Lightweight Charts
| Ticker | Filing Date | Transaction Date | Company | Insider | Title | Transaction | Trade Count | Shares | Avg. Price | Total Value | Position Size Change | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OTLK | 2026-06-03 | 2026-06-02 | Outlook Therapeutics, Inc. | Haddadin Yezan Munther | Director | Buy | 1 | 29,000 | $0.83 | $24,070.00 | 43.83% | View Filing |
| OTLK | 2026-06-01 | 2026-05-28 | Outlook Therapeutics, Inc. | Sukhtian Ghiath M. | Director,TenPercentOwner | Buy | 1 | 8,539,709 | $0.59 | $5,038,428.31 | 38.66% | View Filing |
| OTLK | 2026-06-01 | 2026-05-28 | Outlook Therapeutics, Inc. | Gms Ventures & Investments | Director,TenPercentOwner | Buy | 1 | 8,539,709 | $0.59 | $5,038,428.31 | 38.66% | View Filing |
| OTLK | 2026-05-27 | 2026-05-26 | Outlook Therapeutics, Inc. | Haddadin Yezan Munther | Director | Buy | 1 | 34,000 | $0.44 | $14,960.00 | 91.48% | View Filing |
| OTLK | 2026-05-27 | 2026-05-26 | Outlook Therapeutics, Inc. | Thurman Randy H | Director | Buy | 1 | 5,000 | $0.43 | $2,150.00 | 89.40% | View Filing |
| OTLK | 2024-09-30 | 2024-09-26 | Outlook Therapeutics, Inc. | Kenyon Lawrence A | Chief Financial Officer | Buy | 1 | 5,000 | $5.69 | $28,450.00 | 84.09% | View Filing |
| OTLK | 2024-03-11 | 2024-03-07 | Outlook Therapeutics, Inc. | Evanson Jeff | CHIEF COMMERCIAL OFFICER | Buy | 1 | 62,484 | $0.42 | $26,243.28 | 7.73% | View Filing |
| OTLK | 2022-10-05 | 2022-10-05 | Outlook Therapeutics, Inc. | Hilzinger Kurt J | Director | Buy | 2 | 111,203 | $1.28 | $142,512.15 | 11.95% | View Filing |
| OTLK | 2022-06-23 | 2022-06-21 | Outlook Therapeutics, Inc. | Dagnon Terry | Chief Operating Officer | Buy | 1 | 10,000 | $1.05 | $10,500.00 | 0.85% | View Filing |
| OTLK | 2021-12-02 | 2021-12-02 | Outlook Therapeutics, Inc. | Sukhtian Faisal Ghiath | Director | Buy | 1 | 18,000 | $1.40 | $25,200.00 | 47.37% | View Filing |
⚠️ THE SAMPLE ABOVE IS DEFERRED BY 6 HOURS ⚠️
Start your 2-week, no-credit-card free trial today to receive get down to the second insider trading updates in this directory or email.
Pricing
Free Trial
10 trading days$0
Explore every Premium feature before you pay.
- Full platform access
- 10 trading days
- No credit card required
- 20 years of alert history
- Live alert directory updates
Standard Monthly
Scheduled$19.99 / month
Scheduled alerts with complete trade context.
- Email and Telegram delivery
- Alert intervals from every sixty minutes to once daily
- Filter by insider title, buy/sell, transaction value, DRIP, ESPP, 10b5-1, and tax liability coverage transfers
- Highlighted cluster transactions and SEC filing links
- Access to the alert directory hourly refreshes
Premium Monthly
Recommended$29.99 / month
Fastest alerts with ticker-level control.
- Everything in Standard
- Instant delivery detection-to-outbound time averages 1.32 seconds
- Alert intervals starting from one minute
- Real time alert directory updates
Student discount: Customers who sign up with a verified .edu email address receive 50% off for the first four years. On monthly plans, the first month is the full 75% off.
Alerts are based on public SEC filings and are provided for informational purposes only; they do not constitute financial advice.